Silver Book

Silver Book Fact

Survival Rates Over 5 Years for Patients with Medically Managed Severe Aortic Stenosis

Clark M, Arnold S, Duhay F, et al. Five-Year Clinical and Economic Outcomes Among Patients with Medically Managed Severe Aortic Stenosis: Results from a Medicare claims analysis. Circulation: Cardiovascular Quality and Outcomes. 2012; 5(5). http://circoutcomes.ahajournals.org/content/5/5/697

Reference

Title
Five-Year Clinical and Economic Outcomes Among Patients with Medically Managed Severe Aortic Stenosis: Results from a Medicare claims analysis.
Publication
Circulation: Cardiovascular Quality and Outcomes
Publication Date
2012
Authors
Clark M, Arnold S, Duhay F, et al
Volume & Issue
Volume 5, Issue 5
URL
Read Full Resource

Categories

  • Cost of Disease
  • Human Burden

Publications

Aortic Stenosis Fact Sheet

 https://www.silverbook.org/wp-content/uploads/2017/10/AS-FS-cover.png Thumbnail

Connected Facts

Aortic Stenosis

Projections of Significant Heart Valve Disease — Diagnosed & Undiagnosed — in the 65+ U.K. Population

Future Economic Burden

Aortic Stenosis

Five-year health care resource use in medically managed SAS patients

Economic Burden

Aortic Stenosis

Mean 5-Year Cumulative Total Medical Costs Per Medically Managed (No AVR) Severe AS Patient

Economic Burden

Aortic Stenosis

SAS patient hospitalization costs

Symptomatic aortic stenosis (SAS) patients who do not undergo treatment cost Medicare as much as $1.3 billion each year due to rehospitalization, prolonged stays, admissions to skilled nursing facilities, and use of hospice care.

Economic Burden

Aortic Stenosis

Aortic valve disease costs

Aortic valve disease (AVD) (symptomatic and asymptomatic) costs the U.S. $10.2 billion in direct costs each year.

Economic Burden

Aortic Stenosis

Increased hospital admissions and prolonged length of stay for patients who do not undergo treatment

Medicare severe symptomatic aortic stenosis (sSAS) patients who do not undergo treatment have an average of 1.9 hospital admissions per year and prolonged lengths of stay — 11.5 hospital days per patient-year.

Human Burden

Aortic Stenosis

All-cause mortality for aortic valve disorders

In 2014, all-cause mortality for aortic valve disorders was 34,408 in the U.S.

Human Burden

Aortic Stenosis

1 and 6-month mortality rates without treatment for sSAS

Waiting for treatment for severe symptomatic aortic stenosis (sSAS) can be deadly, with 1-month mortality at 3.7% and 6-month mortality at 11.6% (measured from the time intervention was recommended).

Human Burden

Aortic Stenosis

Lifespan of Medicare patients with sSAS who do not undergo treatment

Medicare patients with severe symptomatic aortic stenosis (sSAS) who do not undergo treatment have an average lifespan of 1.8 years.

Human Burden

Aortic Stenosis

Survival rates of sSAS patients who do not undergo valve replacement

Patients with severe symptomatic aortic stenosis (sSAS) who do not undergo valve replacement have survival rates as low as 50% at two years and 20% at 5 years after the onset of symptoms.

Human Burden

Related Facts

  • Undertreatment of patients with sSAS
    AS is often undertreated — one study found that 56% of severe symptomatic aortic stenosis (sSAS) patients referred to a cardiothoracic surgeon were not operated on.  
  • All-cause mortality for aortic valve disorders
    In 2014, all-cause mortality for aortic valve disorders was 34,408 in the U.S.  
  • Prevalence of AS in Americans 75+
    An estimated 12.4%, or ~2.5 million people ages 75+ in North America, have AS.  
  • Lifespan of Medicare patients with sSAS who do not undergo treatment
    Medicare patients with severe symptomatic aortic stenosis (sSAS) who do not undergo treatment have an average lifespan of 1.8 years.  
  • 2016 prevalence of aortic valve disease in America
    In 2016, as many as 5.8 million U.S. adults had aortic valve disease (AVD). Note: Alliance for Aging Research generated statistic, based on 2005 percentage prevalence estimates by Bach et al. 2007